28.24 USD
+0.32 (+1.15%)
At close: Feb 3, 2026
28.24 USD
0 (0%)
After Hours: 2/3/2026, 8:00:00 PM
Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 191 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
- In the past year AMPH was profitable.
- AMPH had a positive operating cash flow in the past year.
- In the past 5 years AMPH has always been profitable.
- Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of AMPH (6.70%) is better than 87.96% of its industry peers.
- Looking at the Return On Equity, with a value of 14.37%, AMPH belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 8.51%, AMPH belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
- AMPH had an Average Return On Invested Capital over the past 3 years of 12.92%. This is in line with the industry average of 12.83%.
- The last Return On Invested Capital (8.51%) for AMPH is well below the 3 year average (12.92%), which needs to be investigated, but indicates that AMPH had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
- AMPH has a Profit Margin of 15.43%. This is amongst the best in the industry. AMPH outperforms 87.43% of its industry peers.
- AMPH's Profit Margin has improved in the last couple of years.
- The Operating Margin of AMPH (20.73%) is better than 88.48% of its industry peers.
- AMPH's Operating Margin has improved in the last couple of years.
- The Gross Margin of AMPH (49.36%) is better than 64.40% of its industry peers.
- AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
- The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
- Compared to 5 years ago, AMPH has more shares outstanding
- The debt/assets ratio for AMPH has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.46 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
- AMPH's Altman-Z score of 2.46 is fine compared to the rest of the industry. AMPH outperforms 64.40% of its industry peers.
- The Debt to FCF ratio of AMPH is 5.49, which is a neutral value as it means it would take AMPH, 5.49 years of fcf income to pay off all of its debts.
- AMPH's Debt to FCF ratio of 5.49 is amongst the best of the industry. AMPH outperforms 83.25% of its industry peers.
- AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.78, AMPH is not doing good in the industry: 70.16% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.46 |
ROIC/WACC0.94
WACC9.08%
2.3 Liquidity
- AMPH has a Current Ratio of 3.12. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
- AMPH's Current ratio of 3.12 is in line compared to the rest of the industry. AMPH outperforms 52.88% of its industry peers.
- AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
- AMPH has a Quick ratio (2.21) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.95%.
- AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
- The Revenue has decreased by -0.03% in the past year.
- The Revenue has been growing by 17.82% on average over the past years. This is quite good.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
- AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.14% yearly.
- The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 8.21, which indicates a very decent valuation of AMPH.
- AMPH's Price/Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 92.15% of the companies in the same industry.
- When comparing the Price/Earnings ratio of AMPH to the average of the S&P500 Index (28.18), we can say AMPH is valued rather cheaply.
- The Price/Forward Earnings ratio is 7.60, which indicates a rather cheap valuation of AMPH.
- Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 92.15% of the companies are valued more expensively.
- AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.21 | ||
| Fwd PE | 7.6 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
- AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 89.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.69 | ||
| EV/EBITDA | 7.75 |
4.3 Compensation for Growth
- The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
5. Dividend
5.1 Amount
- AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.24
+0.32 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners74.02%
Inst Owner Change-1.44%
Ins Owners9.38%
Ins Owner Change-0.09%
Market Cap1.30B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target32.2 (14.02%)
Short Float %10.93%
Short Ratio10.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-0.45%
PT rev (3m)-4.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.29%
EPS NY rev (1m)0%
EPS NY rev (3m)3.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.21 | ||
| Fwd PE | 7.6 | ||
| P/S | 1.79 | ||
| P/FCF | 11.69 | ||
| P/OCF | 8.52 | ||
| P/B | 1.67 | ||
| P/tB | 6.35 | ||
| EV/EBITDA | 7.75 |
EPS(TTM)3.44
EY12.18%
EPS(NY)3.71
Fwd EY13.16%
FCF(TTM)2.42
FCFY8.55%
OCF(TTM)3.31
OCFY11.73%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.13
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.46 |
F-Score5
WACC9.08%
ROIC/WACC0.94
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.1%
EBIT Next 3Y1.2%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?
The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 8.21 and the Price/Book (PB) ratio is 1.67.